Popular search terms:
Search Results
95 results found-
CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States.
https://www.cslseqirus.us/news/csl-seqirus-begins-shipping-its-portfolio-of-influenza-vaccines-for-the-2024-25-flu-season -
Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.
https://www.cslseqirus.us/expertise/influenza -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.us/news -
CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.cslseqirus.us/expertise -
CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.
https://www.cslseqirus.us/products -
CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
https://www.cslseqirus.us/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza -
A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States.
https://www.cslseqirus.us/news/recently-published-rwe-study-shows-effectiveness-of-cell-based-quad-flu-vaccine-over-3-seasons -
CSL Seqirus confirms it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season -
CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions -
The U.S. Food and Drug Administration (FDA), in collaboration with the World Health Organization (WHO), has directed influenza vaccine manufacturers to remove the B/Yamagata influenza virus strain from all influenza vaccines distributed in the United States, as soon as possible, preferably by the 2024/25 influenza season.
https://www.cslseqirus.us/news/csl-seqirus-to-remove-byamagata-influenza-virus-strain-from-portfolio-of-influenza-vaccines